MCID: MRK002
MIFTS: 33

Marek Disease malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Marek Disease

Aliases & Descriptions for Marek Disease:

Name: Marek Disease 50 69
Neurolymphomatosis 50 56
Marek's Disease 50
Fowl Paralyses 50
Fowl Paralysis 50

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA206586

Summaries for Marek Disease

MalaCards based summary : Marek Disease, also known as neurolymphomatosis, is related to lymphoma and porencephaly 2. An important gene associated with Marek Disease is HMGCR (3-Hydroxy-3-Methylglutaryl-CoA Reductase), and among its related pathways/superpathways are UVA-Induced MAPK Signaling and MAPK Signaling: Oxidative Stress Pathway. The drugs Dopamine and Nitroglycerin have been mentioned in the context of this disorder. Affiliated tissues include t cells, and related phenotype is liver/biliary system.

Wikipedia : 71 Marek\'s disease is a highly contagious viral neoplastic disease in chickens. It is named after József... more...

Related Diseases for Marek Disease

Graphical network of the top 20 diseases related to Marek Disease:



Diseases related to Marek Disease

Symptoms & Phenotypes for Marek Disease

MGI Mouse Phenotypes related to Marek Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 8.92 ACE HMGCR JUN TP53

Drugs & Therapeutics for Marek Disease

Drugs for Marek Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
3
Selenium Approved, Vet_approved Phase 4 7782-49-2
4
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3
11 Adrenergic Agents Phase 4,Phase 2,Phase 3
12 Adrenergic Agonists Phase 4,Phase 2,Phase 3
13 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
16 Vasodilator Agents Phase 4,Phase 2,Phase 3
17 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
18 Hypolipidemic Agents Phase 4,Phase 3
19 Protective Agents Phase 4,Phase 2,Phase 3
20 Lipid Regulating Agents Phase 4
21 Antimetabolites Phase 4,Phase 3,Phase 2
22 Autonomic Agents Phase 4,Phase 3,Phase 2
23 Sodium Channel Blockers Phase 4
24 Adrenergic beta-Antagonists Phase 4
25 Trace Elements Phase 4,Phase 3
26 Diuretics, Potassium Sparing Phase 4
27 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Micronutrients Phase 4,Phase 3
29 Antioxidants Phase 4
30
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
31 Serotonin 5-HT2 Receptor Antagonists Phase 4
32 Serotonin Agents Phase 4,Phase 3,Phase 2
33 Serotonin Antagonists Phase 4
34 Adrenergic Antagonists Phase 4
35 Tranquilizing Agents Phase 4
36 Paliperidone Palmitate Phase 4
37 Dopamine Antagonists Phase 4
38 Dopamine D2 Receptor Antagonists Phase 4
39 Psychotropic Drugs Phase 4,Phase 3
40 Antihypertensive Agents Phase 4,Phase 3
41 Antipsychotic Agents Phase 4
42 Central Nervous System Depressants Phase 4
43 Rosuvastatin Calcium Phase 4 147098-20-2
44 Adrenergic beta-1 Receptor Antagonists Phase 4
45 Sympatholytics Phase 4
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
47 Anticholesteremic Agents Phase 4
48 Calcium, Dietary Phase 4
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
50
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 103)
id Name Status NCT ID Phase
1 Selenium Supplementation in Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT00186706 Phase 4
2 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Completed NCT01425359 Phase 4
3 ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients Completed NCT01323764 Phase 4
4 Effects of Brain Beta-Amyloid on Postoperative Cognition Recruiting NCT01606488 Phase 4
5 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
6 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
7 European Long-acting Antipsychotics in Schizophrenia Trial Recruiting NCT02146547 Phase 4
8 European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) Recruiting NCT00776087 Phase 4
9 Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients? Terminated NCT01605370 Phase 4
10 Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients Terminated NCT00673582 Phase 4
11 Preoperative Radiotherapy and Local Excision in Rectal Cancer Unknown status NCT00738790 Phase 3
12 The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer Unknown status NCT00833131 Phase 3
13 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3
14 Levosimendan Versus Dobutamine in Shock Patients Unknown status NCT00093301 Phase 2, Phase 3
15 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
16 A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Completed NCT01158560 Phase 3
17 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure Recruiting NCT01877915 Phase 3
18 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3
19 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3
20 Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection Recruiting NCT02395848 Phase 3
21 A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Recruiting NCT02493868 Phase 3
22 Secondary Prevention of Cardiovascular Disease in the Elderly Trial Recruiting NCT02596126 Phase 3
23 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Recruiting NCT01951326 Phase 3
24 Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors Recruiting NCT02683941 Phase 3
25 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3
26 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1) Recruiting NCT02163759 Phase 3
27 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3
28 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Recruiting NCT02435992 Phase 3
29 Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Recruiting NCT02531126 Phase 3
30 Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis Recruiting NCT02308111 Phase 3
31 Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC Recruiting NCT02654587 Phase 3
32 CNS Prophylaxis in Diffuse Large B-cell Lymphoma Recruiting NCT02777736 Phase 3
33 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Recruiting NCT02685709 Phase 3
34 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
35 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Recruiting NCT01786278 Phase 2, Phase 3
36 Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome Recruiting NCT02297945 Phase 3
37 Treatment for Endogenous Cushing's Syndrome Recruiting NCT01838551 Phase 3
38 The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer Recruiting NCT01787539 Phase 2, Phase 3
39 Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Active, not recruiting NCT01389167 Phase 3
40 MSB11022 in Moderate to Severe Rheumatoid Arthritis Active, not recruiting NCT03052322 Phase 3
41 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975376 Phase 3
42 Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia Terminated NCT00435448 Phase 3
43 Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer Unknown status NCT01195298 Phase 2
44 Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression Completed NCT00134784 Phase 2
45 Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families Completed NCT00273351 Phase 2
46 A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease Completed NCT00117819 Phase 2
47 Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease Completed NCT01137526 Phase 2
48 Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome Completed NCT00132626 Phase 2
49 Brief Introductory Therapy for Opioid Dependence Completed NCT00406484 Phase 2
50 0.5M Na Lactate Solution in Acute Heart Failure (AHF) Completed NCT01981655 Phase 2

Search NIH Clinical Center for Marek Disease

Genetic Tests for Marek Disease

Anatomical Context for Marek Disease

MalaCards organs/tissues related to Marek Disease:

39
T Cells

Publications for Marek Disease

Articles related to Marek Disease:

id Title Authors Year
1
The 132 bp repeats are present in RNA transcripts from 1.8 kb gene family of Marek disease virus-transformed cells. ( 8105666 )
1993
2
Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. ( 1315048 )
1992
3
The structure of Marek disease virus DNA: the presence of unique expansion in nonpathogenic viral DNA. ( 2983314 )
1985
4
Extensive homology exists between Marek disease herpesvirus and its vaccine virus, herpesvirus of turkeys. ( 6328512 )
1984
5
Inverted repeat nucleotide sequences in the genomes of Marek disease virus and the herpesvirus of the turkey. ( 6281774 )
1982

Variations for Marek Disease

Expression for Marek Disease

Search GEO for disease gene expression data for Marek Disease.

Pathways for Marek Disease

GO Terms for Marek Disease

Biological processes related to Marek Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.54 JUN TNFRSF8 TP53
2 positive regulation of apoptotic process GO:0043065 9.43 JUN TNFRSF8 TP53
3 Ras protein signal transduction GO:0007265 9.4 JUN TP53
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.32 HMGCR JUN
5 positive regulation of neuron apoptotic process GO:0043525 9.16 JUN TP53
6 protein tetramerization GO:0051262 8.96 HMGCR TP53
7 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 8.62 JUN TP53

Molecular functions related to Marek Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2A binding GO:0051721 8.62 HMGCR TP53

Sources for Marek Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....